Known targets — ChEMBL curated mechanism
823298382338688239847Rdl1Rdl2Rdl3
The experimentally established mechanism targets of Lindane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448453 | 0.94 | HDAC3 (0.41) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Phosphoric Acid SCHEMBL19406123 | 0.88 | HDAC3 (0.42) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL58561 | 0.83 | TSHR (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride SCHEMBL6346 | 0.82 | TSHR (0.47) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL936121 | 0.81 | TSHR (0.44) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1720269 | 0.81 | SMN1; SMN2 (0.41) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride SCHEMBL29274482 | 0.80 | TSHR (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Lindane SCHEMBL8715633 | 0.80 | POLB (0.37) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Lindane SCHEMBL20797313 | 0.74 | TSHR (0.36) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7207252 | 0.74 | NPSR1 (0.36) | SIRT2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129377-A1 | Process for Preparing Substituted Aryl Cycloalkanol Derivatives | WYETH (US) | 2007-06-07 | — | — | US | claimed |
| US-8334364-B2 | High-molecular weight derivative of nucleic acid antimetabolite | NIPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20090281300-A1 | HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20080249177-A1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. | 2008-10-09 | — | — | US | disclosed |
| EP-1242404-B1 | PHENOXYPROPANOLAMINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-07-07 | — | — | EP | disclosed |
| WO-1995016675-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
| EP-0401676-A1 | Enzyme inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281300-A1 | HIGH-MOLECULAR WEIGHT DERIVATIVE OF NUCLEIC ACID ANTIMETABOLITE | POLRMT, POLN, POLI | SIRT2 3472/4885HDAC3 1126/4885HDAC4 1101/4885 |
| US-20070129377-A1 | Process for Preparing Substituted Aryl Cycloalkanol Derivatives | CYP1A2, CYP3A7, CYP3A43 | SIRT2 4415/4885HDAC3 2979/4885HDAC4 4471/4885 |
| US-20080249177-A1 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | ADRB3, ADRA2C, ADRA1A | SIRT2 3719/4885HDAC3 1059/4885HDAC4 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.